TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03885882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E0302 SR1
Description: E0302 SR1, oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E0302 SR3
Description: E0302 SR3, oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E0302 SR2
Description: E0302 SR2, oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E0302 SR2
Description: E0302 SR2, oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E0302 IR
Description: E0302 IR, oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E0302 IR
Description: E0302 IR, oral tablet.
Study: NCT03440541

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: REGE pro
Description: REGE pro is a patch of human amniotic membrane sterilized by gamma radiation
Study: NCT04146363

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Subcutaneous injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous Injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous Injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous Injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Injection
Study: NCT01953822

Intervention type: OTHER
Intervention: Data collection
Description: Data collection from an existing electronic healthcare databases - Clinical Practice Research Datalink (CPRD) GOLD.

Intervention type: OTHER
Intervention: Data collection
Description: Data collection from an existing electronic healthcare databases - Clinical Practice Research Datalink (CPRD) GOLD.

Intervention type: OTHER
Intervention: Data collection
Description: Data collection from an existing electronic healthcare databases - Clinical Practice Research Datalink (CPRD) GOLD.

Intervention type: OTHER
Intervention: Data collection
Description: Data collection from an existing electronic healthcare databases - Clinical Practice Research Datalink (CPRD) GOLD.
Study: NCT06227624

Intervention type: DRUG
Group type: OTHER
Intervention: Oral zinc sulfate and standard phototherapy
Description: study the role of oral zinc sulfate in reducing level of indirect hyperbilirubinemia in neonates if used with standard phototherapy
Study: NCT00692146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1386
Description: Oral solution fixed dose (95 mg given orally on two occasions)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution fixed dose (95 mg given orally on two occasions)
Study: NCT05369468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine as adjuvant with bupivacaine
Description: to assess efficacy of adding dexmedetomidine as adjuvant with bupivacaine in ultrasound-guided erector spinae plane block in patient undergoing laporoscopic cholecystectomy. primary outcome was the total amount of morphine consumption in the first 24-hour postoperative, and the secondary outcomes were the time of first rescue analgesia ,pain score, and safety.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacain only
Description: to assess efficacy of bupivacain alone in ultrasound-guided erector spinae plane block in patient undergoing laporoscopic cholecystectomy. primary outcome was the total amount of morphine consumption in the first 24-hour postoperative, and the secondary outcomes were the time of first rescue analgesia ,pain score, and safety.
Study: NCT01947231

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Postural Re-education
Description: Global Postural Re-education is a physical therapy method comprising a series of gentle active movements, implemented by the therapist using manual contacts and verbal commands, to promote postural symmetry.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard manual physical therapy
Description: Standard manual physical therapy in this study involves a combination of exercises, pompage (gentle manual techniques of distraction and articulation of a joint), anterior-posterior mobilizations as described by Maitland, and massage that have been selected to meet the needs of each individual patient.
Study: NCT01565265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pergoveris in long protocol with GnRH agonist
Description: Ovarian hyperstimulation with recombinant FSH and recombinant FSH Ovulation induction with recombinant HCG Oocyte collection for ICSI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pergoveris in GnRH antagonist protocol
Description: Ovarian hyperstimulation with recombinant FSH and recombinant FSH Ovulation induction with recombinant HCG Oocyte collection for ICSI
Study: NCT02349620

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRF
Description: implant stability was measured by RFA and implant resorption was measured by IOPA after surface treatment by PRF
Study: NCT00653991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOLVE-IT
Description: SOLVE-IT, a video game using computer-generated virtual agents, is the next generation of interactive media aimed at reducing risky sex among young MSM. Participants will interact in a virtual environment that focuses upon HIV prevention in a dating context.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SOLVE-IT
Description: SOLVE-IT, a video game using computer-generated virtual agents, is the next generation of interactive media aimed at reducing risky sex among young MSM. Participants will interact in a virtual environment that focuses upon HIV prevention in a dating context.
Study: NCT02192008

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Salmonella Typhi

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Salmonella Typhi

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Salmonella Paratyphi

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Salmonella Paratyphi
Study: NCT03102593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-113
Description: ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-113
Description: ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly
Study: NCT00537108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home visiting and care management
Description: Third trimester teens are assigned a Care Manager (CM) who establishes a continuity relationship and provides monthly visits until the index child is 2 years old. Core services for intervention group include: 1)Baseline and ongoing assessment of health, mental health, housing, daycare, and school needs; 2)Administration of a culturally sensitive, developmentally relevant parenting curriculum; 3)Computer Assisted Motivational Interviewing to promote healthy relationships, improve contraceptive practices, focus on goals, and promote school continuation; 4)Efforts to engage the young father; 5)Linkage and coordination with primary care for teen, child, young father; 6)Support \& skills-building for school continuation, higher education, and job readiness.
Study: NCT02516423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixazomib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zoledronic acid
Description: IV
Study: NCT03946254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effect of strength training on executive functions in elderly people with mild cognitive impairment.
Description: Strength training sessions will have a frequency of 3 times per week (Monday, Tuesday and Wednesday) for 20 weeks. In addition, each subject is subject to an individualized training program according to the workload in order to progressively increase the intensity of work. The workload will be modified progressively by influencing both the total volume of repetitions and the intensity of the exercises. The exercises will be controlled movements and not harmful, as guided machines will be used to facilitate the execution of actions. In addition, the largest amount of muscle groups to be able to generate strength gains in all muscle groups. The control group will perform breathing exercises and low intensity stretching during the same days and with the same duration as the experimental group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effect of strength training on executive functions in elderly people with mild cognitive impairment.
Description: Strength training sessions will have a frequency of 3 times per week (Monday, Tuesday and Wednesday) for 20 weeks. In addition, each subject is subject to an individualized training program according to the workload in order to progressively increase the intensity of work. The workload will be modified progressively by influencing both the total volume of repetitions and the intensity of the exercises. The exercises will be controlled movements and not harmful, as guided machines will be used to facilitate the execution of actions. In addition, the largest amount of muscle groups to be able to generate strength gains in all muscle groups. The control group will perform breathing exercises and low intensity stretching during the same days and with the same duration as the experimental group
Study: NCT02314572

Intervention type: DEVICE
Group type: OTHER
Intervention: Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses
Description: Binocular implantation of the combination of AcrySof® IQ ReSTOR® multifocal intraocular lenses with an addition of +2.5 D in the distance-dominant eye and +3.0 D in the fellow eye.
Study: NCT01919450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson
Description: Subjects will undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson
Description: Subjects will undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson
Description: Subjects will undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Rubidium-82
Description: Subjects undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Rubidium-82
Description: Subjects undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Rubidium-82
Description: Subjects undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Rubidium-82
Description: Subjects undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
Study: NCT01000480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 milligrams per square meter (mg/m²) intravenous infusion on Day 1 of a 21 day cycle for 2 cycles: with possibility of 2 additional cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m² intravenous infusion on Day 1 of a 21 day cycle for 2 cycles; with the possibility of 2 additional cycles.
Study: NCT03643796

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil infusion of 0.05 to 0.2 mcg/kg/minute started just prior to induction and stopped at emergence from anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine infusion of 2 mcg/kg/minute will be started at induction. It will be stopped at the beginning of the emergence from anesthesia, roughly 45 minutes from extubation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine bolus of 0.5 mcg/kg over 10 minutes starting 5 minutes prior to induction followed by an infusion of 0.2-0.7 mcg/kg/hour that will be stopped with the start of closing the surgical wound.
Study: NCT01000480

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiotherapy
Description: Administered at 2 gray (Gy)/fraction after completion of the pemetrexed and cisplatin infusions on Day 1 of Cycle 3 and will continue daily (5 days per week) until the total delivered dose reaches a therapeutic goal of 66 Gy, over approximately 7 weeks.
Study: NCT02561702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 240 mg lactose powder in a size 3 capsule taken by mouth 3 times daily for 5-7 days
Study: NCT01413542

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bradykinin
Description: bradykinin intra-brachial artery (23.6, 47.2, and 94.3 pmol/min)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: enalaprilat (ACE inhibitor)
Description: intra-brachial artery(0.33 µg/min per 100 mL forearm volume)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: enalaprilat (ACE inhibitor)
Description: intra-brachial artery(0.33 µg/min per 100 mL forearm volume)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucagon-like peptide 1
Description: intra-brachial artery (0.45-3.60 pmol/min)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucagon-like peptide 1
Description: intra-brachial artery (0.45-3.60 pmol/min)
Study: NCT02827721

Intervention type: DEVICE
Intervention: multiple breath washout test
Study: NCT03423641

Intervention type: DRUG
Intervention: Direct Acting Antivirals
Description: The time period during which a patient is dispensed the medication and for up to 180 days after initiation of the medication.
Study: NCT00270790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine
Description: Amifostine will be given at dose of 500 mg IV within one hour before radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin for 100 mg/m2 and will be administered after the taxol infusion
Study: NCT01413542

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: brain natriuretic peptide
Description: Intra-brachial artery (0.90, 1.80 and 3.6 pmol/min)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: brain natriuretic peptide
Description: Intra-brachial artery (0.90, 1.80 and 3.6 pmol/min)
Study: NCT02279121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taurolock
Description: At the beginning of each course of IV anti-tumor treatment, a nurse removes the lock TauroLock ™ and makes rinsing the CVC. At the end of each course, she rinses again the CVC and instills TauroLock ™ solution. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study

Intervention type: DRUG
Group type: OTHER
Intervention: saline solution
Description: At the beginning of each course of IV anti-tumor treatment, a nurse makes rinsing the CVC. At the end of each course, she rinses again the CVC. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study
Study: NCT01556802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocicline
Description: Minocicline 100mg oral twice a day for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pills with vegetable fibers one pill oral twice a day for five days
Study: NCT02827721

Intervention type: DEVICE
Intervention: multiple breath washout test

Intervention type: DEVICE
Intervention: body plethysmography
Study: NCT00270790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: Taxol will be given at a dose of 40 mg/m2 as a 3 hour infusion dose

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation will be given at a dose of 1.8 Gy. for a total of 70.2 Gy
Study: NCT00332007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tonabersat
Description: two tablets once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two tablets once daily
Study: NCT01919593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate in 70% alcohol
Description: skin preparation before venipuncture for blood culture in even month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10%povidone iodine
Description: skin preparation before venipuncture for blood culture in odd month
Study: NCT04655378

Intervention type: OTHER
Intervention: Mass Sepctrometry
Description: Mass spectrometry (LC/MS) of purified immunoglobulins

Intervention type: OTHER
Intervention: Mass Sepctrometry
Description: Mass spectrometry (LC/MS) of purified immunoglobulins

Intervention type: OTHER
Intervention: Mass Sepctrometry
Description: Mass spectrometry (LC/MS) of purified immunoglobulins
Study: NCT02171377

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: group 2 : quadricipital electrical stimulation
Description: bilateral quadricipital electrical stimulation 5 sessions a week, (6 - 8 weeks)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pulmonary rehabilitation
Description: exercise training, 3 to 5 times per week, 8 weeks
Study: NCT02827721

Intervention type: DEVICE
Intervention: body plethysmography
Study: NCT02668289

Intervention type: OTHER
Group type: OTHER
Intervention: consent
Description: At the initial screening examination, each subject will receive an informed consent form. Prior to signing the informed consent, one of the investigators or qualified staff will thoroughly discuss participation in the study with each subject, allocating time for questions and answers.

Intervention type: OTHER
Group type: OTHER
Intervention: Screening
Description: At the initial screening examination, complete medical and dental history will be obtained to verify eligibility.

Intervention type: OTHER
Group type: OTHER
Intervention: Xray
Description: each subject will undergo site-specific oral radiographic exam (new periapical radiographs will be obtained if needed) to evaluate potential study sites.

Intervention type: OTHER
Group type: OTHER
Intervention: PVS Impressions
Description: PVS impressions of the arch of interest will be obtained in order perform volumetric analysis of the area of interest.

Intervention type: OTHER
Group type: OTHER
Intervention: Photographs
Description: Intraoral photographs will also be taken and subsequent study visits will be planned.

Intervention type: OTHER
Group type: OTHER
Intervention: CBCT
Description: The patient will then be sent to the Department of Radiology at the College of Dentistry for a baseline CBCT and follow-up at 14 week CBCT. These CBCT's will be utilized to evaluate the hard tissue volume in comparison to the clinical volume of soft tissue.

Intervention type: OTHER
Group type: OTHER
Intervention: Anesthesia
Description: After appropriate local anesthetic is administered and anesthesia is achieved, the buccal tissue thickness will be measured and recorded.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Extraction
Description: After the pre-extraction baseline measurements are recorded and adequate anesthesia is confirmed, minimally invasive extraction procedures will be initiated. All extractions will be performed by residents in the UI CoD Periodontics advanced education program.

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical measurements
Description: Measuring soft tissue dimensions, bone thickness prior to and immediately after extraction and then after appropriate healing time frames.
Study: NCT02832570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 100mg single oral dose
Description: Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Oral intake single dose
Description: Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)
Study: NCT03134326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: R1-25 and R2-25 Pulse Oximeter Sensor
Study: NCT02171377

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: muscular electrical stimulation
Description: Bilateral quadricipital electrical stimulation 30 min, 5 times per week, 8 weeks,in addition to pulmonary rehabilitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pulmonary rehabilitation
Description: exercise training, 45 min, 3 to 5 times per week, 8 weeks
Study: NCT01207791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: screening
Description: Brief screening to assess eligibility and collect minimal baseline data

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: screening
Description: Brief screening to assess eligibility and collect minimal baseline data

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: screening
Description: Brief screening to assess eligibility and collect minimal baseline data

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: assessment
Description: comprehensive substance use assessment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: assessment
Description: comprehensive substance use assessment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: referral
Description: referral to treatment if indicated or requested

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: referral
Description: referral to treatment if indicated or requested

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief intervention
Description: 30-minute brief intervention session in ED

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: booster sessions
Description: two 15-minute booster counseling sessions conducted by telephone
Study: NCT01893710

Intervention type: PROCEDURE
Intervention: biopsy sampling
Description: Two parietal peritoneal samples, each 1 cm² x 0.3 cm in depth and three omental tissue samples, each 1 cm² in size will be obtained.~Biopsy sampling will be performed in all groups. This is an observational not an interventional trial.

Intervention type: PROCEDURE
Intervention: biopsy sampling
Description: Two parietal peritoneal samples, each 1 cm² x 0.3 cm in depth and three omental tissue samples, each 1 cm² in size will be obtained.~Biopsy sampling will be performed in all groups. This is an observational not an interventional trial.